With this and the broker report DXB is getting all its ducks in a row prior to the release of the detailed Phase 2 results next week.
Certainly doing its best to avoid a post-consolidation price drop!
Ann: Ethics Committee Approval for Pharmacokinetic Trial, page-2
-
- There are more pages in this discussion • 86 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
45.0¢ |
Change
0.015(3.45%) |
Mkt cap ! $247.7M | |||
| Open | High | Low | Value | Volume |
| 44.0¢ | 46.5¢ | 42.5¢ | $1.090M | 2.454M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 63703 | 45.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 46.0¢ | 35469 | 2 |
View Market Depth
| Last trade - 16.10pm 31/07/2024 (20 minute delay) ? |
| DXB (ASX) Chart |